According to Jazz Pharmaceuticals's latest financial reports the company has a price-to-book ratio of 1.81.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 2.07 | -36.26% |
2022-12-31 | 3.25 | 64.6% |
2021-12-31 | 1.97 | -22.04% |
2020-12-31 | 2.53 | -5.96% |
2019-12-31 | 2.69 | 4.21% |
2018-12-31 | 2.59 | -13.12% |
2017-12-31 | 2.98 | -14.46% |
2016-12-31 | 3.48 | -35.47% |
2015-12-31 | 5.39 | -25.56% |
2014-12-31 | 7.24 | 28.12% |
2013-12-31 | 5.65 | 105.14% |
2012-12-31 | 2.76 | -67.39% |
2011-12-31 | 8.45 | -67.18% |
2010-12-31 | 25.7 | -861.16% |
2009-12-31 | -3.38 | 562.88% |
2008-12-31 | -0.5102 | -107.77% |
2007-12-31 | 6.56 | |
2006-12-31 | N/A | |
2005-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Novartis NVS | 4.30 | 138.08% | ๐จ๐ญ Switzerland |
AmerisourceBergen
ABC | 39.2 | 2,069.52% | ๐บ๐ธ USA |
Endo International
ENDPQ | 0.0000 | -100.00% | ๐ฎ๐ช Ireland |
Teva Pharmaceutical Industries TEVA | 1.81 | 0.35% | ๐ฎ๐ฑ Israel |